Curcumin for maintenance of remission in ulcerative colitis (original) (raw)

The review examines the efficacy of curcumin in maintaining remission in ulcerative colitis patients. Based on a single trial involving 89 patients, curcumin showed a lower relapse rate at six months compared to a placebo (4% vs 18%), though statistical significance was marginal (P=0.06). Clinical and endoscopic activity indices at six months also favored curcumin, with significant improvement over placebo (CAI MD -1.20; EI MD -0.80). At 12 months, relapse rates were not statistically significant. Adverse events were reported but not attributed to treatment groups.